Stanford Peng
2021
In 2021, Stanford Peng earned a total compensation of $2.5M as President and Head of Research and Development at Nivalis Therapeutics, a 149% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $609,400 |
|---|---|
| Option Awards | $1,345,772 |
| Salary | $496,875 |
| Total | $2,452,047 |
Peng received $1.3M in option awards, accounting for 55% of the total pay in 2021.
Peng also received $609.4K in non-equity incentive plan and $496.9K in salary.
Rankings
In 2021, Stanford Peng's compensation ranked 5,228th out of 12,415 executives tracked by ExecPay. In other words, Peng earned more than 57.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,228 out of 12,415 | 58th |
Division Manufacturing | 2,196 out of 5,505 | 60th |
Major group Chemicals And Allied Products | 954 out of 2,375 | 60th |
Industry group Drugs | 852 out of 2,096 | 59th |
Industry Pharmaceutical Preparations | 611 out of 1,546 | 61st |
Source: SEC filing on April 29, 2022.
Peng's colleagues
We found three more compensation records of executives who worked with Stanford Peng at Nivalis Therapeutics in 2021.